ArticleBMC cancer2023

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.

Marie Alt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.